Conflict of interest and source of funding statement
Randomized Clinical Trial
Horizontal ridge augmentation of the atrophic anterior maxilla using rhBMP-2/ACS or autogenous bone grafts: a proof-of-concept randomized clinical trial
Article first published online: 2 SEP 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Journal of Clinical Periodontology
Volume 40, Issue 10, pages 968–975, October 2013
How to Cite
Horizontal ridge augmentation of the atrophic anterior maxilla using rhBMP-2/ACS or autogenous bone grafts: a proof-of-concept randomized clinical trial. J Clin Periodontol 2013; 40: 968–976. doi: 10.1111/jcpe.12148, , , , , , .
The authors declare no conflict of interest for this study. Research funding was provided from the São Paulo Research Foundation (FAPESP – grant number 2009/16016-8), São Paulo, Brazil and CAPES, Brasilia, Brazil. Dr. Susin was supported in part by a 3M Non-Tenured Faculty Grant, St Paul, MN, USA. Drs Wikesjö and Susin were supported in part by a grant from Nobel Biocare AB, Göteborg, Sweden.
- Issue published online: 2 SEP 2013
- Article first published online: 2 SEP 2013
- Accepted manuscript online: 22 JUL 2013 06:58AM EST
- Manuscript Accepted: 16 JUL 2013
- São Paulo Research Foundation. Grant Number: 2009/16016-8
- 3M Non-Tenured Faculty
- Nobel Biocare AB
- alveolar ridge augmentation;
- autogenous bone graft;
- randomized-controlled trial;
- recombinant human bone morphogenetic protein;
To compare the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge carrier (ACS) with autogenous bone graft for augmentation of the edentulous atrophic anterior maxilla.
Twenty-four subjects were enrolled in a randomized, controlled, parallel-group, open-label clinical trial. Subjects either received rhBMP-2/ACS (1.5 mg/ml) or particulated autogenous bone harvested from the mandibular retromolar region. A titanium-mesh was used to provide space and wound stability. A guide was used to standardize clinical recordings using an analogue caliper. Alveolar ridge width was also assessed using cone-beam computed tomography.
rhBMP-2/ACS yielded significantly greater radiographic horizontal bone gain compared with autogenous bone graft at immediate subcrestal levels (1.5 ± 0.7 versus 0.5 ± 0.9 mm; p = 0.01); non-significant differences were observed at mid- (2.9 ± 0.8 versus 2.9 ± 0.9 mm; p = 0.98) and apical (1.7 ± 0.9 versus 1.8 ± 1.1 mm; p = 0.85) crestal levels. No significant differences in clinical horizontal bone gain were observed at 6 months between rhBMP-2/ACS and autogenous bone graft (3.2 ± 0.9 mm versus 3.7 ± 1.4 mm; p = 0.31). Sixty-two implants were placed after 6 month of healing with no significant differences between groups for number of implants, implant size, primary stability and survival.
rhBMP-2/ACS appears a realistic alternative for augmentation of the edentulous atrophic anterior maxilla.